1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Social Media: Use Of Influencers In Drug Promotion Requires Guardrails, Experts Say

 
• By Sue Sutter

Careful identification and vetting of spokespersons, training on FDA regulations, and development of content that conveys the typical patient experience are keys to successful and compliant influencer campaigns, advertising, legal and regulatory experts told a recent DIA conference.

Social media
The FDA's fundamental rules for medical product promotion apply to influencer campaigns on social media. • Source: Shutterstock

Pharmaceutical companies that want to use influencers to promote their products should provide compliance training on US Food and Drug Administration promotional requirements, ensure the content conveys the typical patient experience in line with a drug’s labeling, and set expectations about the need for marketing, legal and regulatory review of content before posting.

Those are some of the rules of the road suggested by regulatory, advertising and legal experts at panel discussions on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

‘Major Statements’ Are Major Target Of US FDA’s New TV Ad Crackdown

 
• By Sarah Karlin-Smith, Cathy Kelly, and Derrick Gingery

The bolus of untitled letters signals the FDA's approach to enforcement of the final rule on the presentation of the major statement in direct-to-consumer TV ads in a clear, conspicuous and neutral matter.

DTC Ad Crackdown: US FDA Focuses On Compounded GLP-1 Marketers

 
• By Cathy Kelly and Sue Sutter

Just eight of the 68 warning letters posted by the FDA to date went to innovator companies, but GLP-1 agonists still were a focus.

US FDA DTC Ad Crackdown Could Force Shift In Spending, Regulatory Focus

 
• By Jessica Merrill

Ad spending changes in response to the FDA's new DTC policy could force the agency to shift the focus of its regulatory resources.

More from Compliance

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.